Physician profile
Robbyn E Ceasar
NPI 1235489758
$4,695.80
in general payments reported to CMS, 2019-2025
27 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.75 · 2023: $813 · 2024: $1,886 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,603 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,602.61 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,295.20 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $678.11 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $664.59 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $472.22 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $256.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $222.36 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $207.25 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $112.88 | 2023-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $100.76 | 2023 | Gattex, Entyvio |
| Janssen Pharmaceuticals, INC | $79.75 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $79.39 | 2023-2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $65.16 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $57.26 | 2025 | Wegovy |
| Organon LLC | $56.94 | 2023-2025 | Renflexis, Hadlima |
| Medtronic, INC. | $48.23 | 2024 | Interstim |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.81 | 2023 | Dificid |
| Novartis Pharmaceuticals Corporation | $32.48 | 2025 | |
| Evoke Pharma, INC. | $29.99 | 2023 | Gimoti |
| Qol Medical, LLC | $28.75 | 2024 | Sucraid |
| Celltrion USA INC. | $27.92 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $25.91 | 2025 | Omvoh |
| Abbott Laboratories | $24.74 | 2025 | Freestyle Libre 3 |
| Laborie Medical Technologies Corp. | $19.10 | 2024 | Endosheath Technology |
| Gilead Sciences, INC. | $18.85 | 2025 | |
| Fresenius Kabi USA, LLC | $17.89 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $16.23 | 2023 | Ocaliva |
| Celgene Corporation | $14.71 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robbyn Ceasar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.